Certara Valuation
Is CERT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CERT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CERT * (MX$359.4) is trading above our estimate of fair value (MX$172.56)
Significantly Below Fair Value: CERT * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CERT *?
Other financial metrics that can be useful for relative valuation.
What is CERT *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$3.85b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 11.7x |
Enterprise Value/EBITDA | 45x |
PEG Ratio | 6.9x |
Price to Sales Ratio vs Peers
How does CERT *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7.4x | ||
SECT B Sectra | 14.9x | 13.9% | kr42.6b |
DOCS Doximity | 9.6x | 9.8% | US$4.5b |
EVH Evolent Health | 1.6x | 14.1% | US$3.1b |
GDRX GoodRx Holdings | 3.5x | 7.6% | US$2.6b |
CERT * Certara | 11.5x | 12.9% | Mex$3.9b |
Price-To-Sales vs Peers: CERT * is good value based on its Price-To-Sales Ratio (11.5x) compared to the peer average (18.3x).
Price to Earnings Ratio vs Industry
How does CERT *'s PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Sales vs Industry: CERT * is expensive based on its Price-To-Sales Ratio (11.5x) compared to the Global Healthcare Services industry average (3.6x).
Price to Sales Ratio vs Fair Ratio
What is CERT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 11.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CERT *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.